Skip to main content
SpringerLink
Log in

Active Surveillance and Focal Therapy: A European Perspective

  • Chapter
  • First Online:
Imaging and Focal Therapy of Early Prostate Cancer

Part of the book series: Current Clinical Urology ((CCU))

Abstract

In Europe, PCa screening is less common than in the USA where guidelines exist. Stage and grade migration in patients diagnosed with clinically localised PCa and treated with RP affect Europe and the USA to a different extent. Treatment of localised PCa varies from active surveillance (AS) to radical prostatectomy (RP) or radiation therapy (RT). Increasing emphasis on better preservation of the quality of life without compromising cancer control has led to increased interest in minimally invasive treatment. Focal therapy aims to offer a “middle ground” between AS and radical therapies. A questionnaire was designed to assess the status of AS and focal therapy for early PCa in Europe. The questionnaire was sent via e-mail to 95 European key opinion leaders treating localised PCa. In total, 32 key opinion leaders (34 %) from ten European countries responded to the questionnaire. Data accounting for approximately 11,665 cases/year were collected. The percentage of patients who were offered AS is presented per country. Focal therapy is still in its infancy. It is currently used by ten European respondents (31 %; 10 of 32). The use of focal therapy modalities in Europe is briefly discussed. We also examined the respondents’ attitude about AS and focal therapy. At present, focal therapy cannot be recommended outside study protocols.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46(4):765–81.

    Article  PubMed  CAS  Google Scholar 

  2. Kvale R, Auvinen A, Adami HO, et al. Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries. J Natl Cancer Inst. 2007; 99(24):1881–7.

    Article  PubMed  Google Scholar 

  3. Bouchardy C, Fioretta G, Rapiti E, et al. Recent trends in prostate cancer mortality show a continuous decrease in several countries. Int J Cancer. 2008;123(2):421–9.

    Article  PubMed  CAS  Google Scholar 

  4. Bray F, Lortet-Tieulent J, Ferlay J, Forman D, Auvinen A. Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eur J Cancer. 2010;46(17):3040–52.

    Article  PubMed  CAS  Google Scholar 

  5. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol. 2010;28(1):126–31.

    Article  PubMed  Google Scholar 

  6. Stattin P, Holmberg E, Johansson JE, Holmberg L, Adolfsson J, Hugosson J. Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study. J Natl Cancer Inst. 2010; 102(13):950–8.

    Article  PubMed  Google Scholar 

  7. Steineck G, Helgesen F, Adolfsson J, et al. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med. 2002;347(11):790–6.

    Article  PubMed  Google Scholar 

  8. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360(13):1320–8.

    Article  PubMed  Google Scholar 

  9. Andriole GL, Crawford ED, Grubb RL, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360(13):1310–9.

    Article  PubMed  CAS  Google Scholar 

  10. Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol. 2010; 11(8):725–32.

    Article  PubMed  Google Scholar 

  11. Wilt TJ, Brawer MK, Barry MJ, et al. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. Contemp Clin Trials. 2009;30(1):81–7.

    Article  PubMed  Google Scholar 

  12. Donovan J, Hamdy F, Neal D, et al. Prostate Testing for Cancer and Treatment (ProtecT) feasibility study. Health Technol Assess. 2003;7(14):1–88.

    PubMed  CAS  Google Scholar 

  13. Lane JA, Hamdy FC, Martin RM, Turner EL, Neal DE, Donovan JL. Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies. Eur J Cancer. 2010; 46(17):3095–101.

    Article  PubMed  CAS  Google Scholar 

  14. Zeliadt SB, Hoffman RM, Etzioni R, Gore JL, Kessler LG, Lin DW. Influence of publication of US and European prostate cancer screening trials on PSA testing practices. J Natl Cancer Inst. 2011; 103(6):520–3.

    Article  PubMed  Google Scholar 

  15. Collin SM, Martin RM, Metcalfe C, et al. Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. Lancet Oncol. 2008;9(5):445–52.

    Article  PubMed  Google Scholar 

  16. Sirovitch BE, Schwarz LM, Woolsin S. Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence? JAMA. 2003;289:1414–20.

    Article  Google Scholar 

  17. Melia J, Moss S, Johns L. Rates of prostate-specific antigen testing in general practice in England and Wales in asymptomatic and symptomatic patients: a cross-sectional study. BJU Int. 2004;94(1):51–6.

    Article  PubMed  Google Scholar 

  18. Eisinger F, Blay JY, Pivot X, et al. Screening for prostate cancer: growth without control. Eur J Cancer Prev. 2011;20 Suppl 1:S33–35.

    Article  PubMed  Google Scholar 

  19. Gallina A, Chun FK, Suardi N, et al. Comparison of stage migration patterns between Europe and the USA: an analysis of 11 350 men treated with radical prostatectomy for prostate cancer. BJU Int. 2008; 101(12):1513–8.

    Article  PubMed  Google Scholar 

  20. Budaus L, Spethmann J, Isbarn H, et al. Inverse stage migration in patients undergoing radical prostatectomy: results of 8916 European patients treated within the last decade. BJU Int. 2011;108(8):1256–61.

    Article  PubMed  Google Scholar 

  21. Heidenreich A, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2011;59(1):61–71.

    Article  PubMed  Google Scholar 

  22. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR. Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol. 2007;178(3 Pt 2):S14–19.

    Article  PubMed  Google Scholar 

  23. Johansson JE, Andren O, Andersson SO, et al. Natural history of early, localized prostate cancer. JAMA. 2004;291(22):2713–9.

    Article  PubMed  CAS  Google Scholar 

  24. Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst. 2003;95(12):868–78.

    Article  PubMed  Google Scholar 

  25. Postma R, Schroder FH, van Leenders GJ, et al. Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)–Section Rotterdam. A comparison of two rounds of screening Eur Urol. 2007;52(1):89–97.

    Google Scholar 

  26. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA. 2005;293(17):2095–101.

    Article  PubMed  CAS  Google Scholar 

  27. Lu-Yao GL, Albertsen PC, Moore DF, et al. Outcomes of localized prostate cancer following conservative management. JAMA. 2009;302(11):1202–9.

    Article  PubMed  CAS  Google Scholar 

  28. Albertsen PC, Moore DF, Shih W, Lin Y, Li H, Lu-Yao GL. Impact of comorbidity on survival among men with localized prostate cancer. J Clin Oncol. 2011; 29(10):1335–41.

    Article  PubMed  Google Scholar 

  29. The National Institute for Health and Clinical Excellence (NICE 2008). Prostate cancer: diagnosis and treatment. http://wwwniceorguk/nicemedia/live/11924/39687/39687pdf. Accessed Jul 2011.

  30. Martin RM, Gunnell D, Hamdy F, Neal D, Lane A, Donovan J. Continuing controversy over monitoring men with localized prostate cancer: a systematic review of programs in the prostate specific antigen era. J Urol. 2006;176(2):439–49.

    Article  PubMed  Google Scholar 

  31. Mohler JL, Williams BT, Freeman JA. Expectant management as an option for men with stage T1c prostate cancer: a preliminary study. World J Urol. 1997;15(6):364–8.

    Article  PubMed  CAS  Google Scholar 

  32. Choo R, Klotz L, Danjoux C, et al. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol. 2002;167(4):1664–9.

    Article  PubMed  Google Scholar 

  33. Chen WM, Yang CR, Ou YC, et al. Clinical outcome of patients with stage T1a prostate cancer. J Chin Med Assoc. 2003;66(4):236–40.

    PubMed  Google Scholar 

  34. Khan MA, Carter HB, Epstein JI, et al. Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer? J Urol. 2003;170(6 Pt 1):2274–8.

    Article  PubMed  Google Scholar 

  35. Patel MI, DeConcini DT, Lopez-Corona E, Ohori M, Wheeler T, Scardino PT. An analysis of men with clinically localized prostate cancer who deferred definitive therapy. J Urol. 2004;171(4):1520–4.

    Article  PubMed  Google Scholar 

  36. National Comprehensive Cancer Network Clinical practice Guidelines in Oncology – Prostate cancer – version 4 – 2011, 06/21/11. National Comprehensive Cancer Network, Inc. 2011. http://www.nccn.org. Assessed 20 Aug 2011.

  37. Soloway MS, Soloway CT, Williams S, Ayyathurai R, Kava B, Manoharan M. Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience. BJU Int. 2008;101(2):165–9.

    PubMed  Google Scholar 

  38. van den Bergh RC, Roemeling S, Roobol MJ, Aus G, Hugosson J, Rannikko AS, et al. Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol. 2009;55(1):1–8.

    Article  PubMed  Google Scholar 

  39. Dall’Era MA, Konety BR, Cowan JE, et al. Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer. 2008;112(12):2664–70.

    Article  PubMed  Google Scholar 

  40. Berglund RK, Masterson TA, Vora KC, Eggener SE, Eastham JA, Guillonneau BD. Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance. J Urol. 2008;180(5):1964–67 (discussion 1967–1968).

    Article  PubMed  Google Scholar 

  41. Al Otaibi M, Ross P, Fahmy N, et al. Role of repeated biopsy of the prostate in predicting disease progression in patients with prostate cancer on active surveillance. Cancer. 2008;113(2):286–92.

    Article  PubMed  Google Scholar 

  42. Kakehi Y, Kamoto T, Shiraishi T, et al. Prospective evaluation of selection criteria for active surveillance in Japanese patients with stage T1cN0M0 prostate cancer. Jpn J Clin Oncol. 2008;38(2):122–8.

    Article  PubMed  Google Scholar 

  43. Heidenreich A, Bolla M, Joniau S, et al. European Association of Urology. Guidelines on prostate cancer. http://wwwuroweborg/gls/pdf/08_Prostate_Cancer%20July%206thpdf. Assessed 20 Jul 2011

  44. Soloway MS, Soloway CT, Eldefrawy A, Acosta K, Kava B, Manoharan M. Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment. Eur Urol. 2010;58(6):831–5.

    Article  PubMed  Google Scholar 

  45. van den Bergh RC, Vasarainen H, van der Poel HG, et al. Short-term outcomes of the prospective multicentre ‘Prostate Cancer Research International: Active Surveillance’ study. BJU Int. 2009;105(7):956–62.

    Article  PubMed  Google Scholar 

  46. van den Bergh RC, Roemeling S, Roobol MJ, Roobol W, Schroder FH, Bangma CH. Prospective validation of active surveillance in prostate cancer: the PRIAS study. Eur Urol. 2007;52(6):1560–3.

    Article  PubMed  Google Scholar 

  47. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2011;364(18):1708–17.

    Article  PubMed  CAS  Google Scholar 

  48. van den Bergh RC, Steyerberg EW, Khatami A, et al. Is delayed radical prostatectomy in men with low-risk screen-detected prostate cancer associated with a higher risk of unfavorable outcomes? Cancer. 2010;116(5):1281–90.

    Article  PubMed  Google Scholar 

  49. Andersson SO, Andren O, Lyth J, et al. Managing localized prostate cancer by radical prostatectomy or watchful waiting: Cost analysis of a randomized trial (SPCG-4). Scand J Urol Nephrol. 2011;45(3):177–83.

    Article  PubMed  Google Scholar 

  50. Barocas DA, Cowan JE, Smith Jr JA, Carroll PR. What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database. J Urol. 2008;180(4):1330–34 (discussion 1334–1335).

    Article  PubMed  Google Scholar 

  51. Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol. 2010;28(7):1117–23.

    Article  PubMed  Google Scholar 

  52. Tseng KS, Landis P, Epstein JI, Trock BJ, Carter HB. Risk stratification of men choosing surveillance for low risk prostate cancer. J Urol. 2010;183(5):1779–85.

    Article  PubMed  CAS  Google Scholar 

  53. Miocinovic R, Jones JS, Pujara AC, Klein EA, Stephenson AJ. Acceptance and durability of surveillance as a management choice in men with screen-detected, low-risk prostate cancer: improved outcomes with stringent enrollment criteria. Urology. 2011; 77(4):980–4.

    Article  PubMed  Google Scholar 

  54. Finelli A, Trottier G, Lawrentschuk N, et al. Impact of 5alpha-reductase inhibitors on men followed by active surveillance for prostate cancer. Eur Urol. 2011;59(4): 509–14.

    Article  PubMed  CAS  Google Scholar 

  55. Jeldres C, Suardi N, Walz J, et al. Validation of the contemporary epstein criteria for insignificant prostate cancer in European men. Eur Urol. 2008;54(6): 1306–13.

    Article  PubMed  Google Scholar 

  56. Isebaert S, Van Audenhove C, Haustermans K, et al. Evaluating a decision aid for patients with localized prostate cancer in clinical practice. Urol Int. 2008; 81(4):383–8.

    Article  PubMed  CAS  Google Scholar 

  57. Gorin MA, Soloway CT, Eldefrawy A, Soloway MS. Factors that influence patient enrollment in active surveillance for low-risk prostate cancer. Urology. 2011; 77(3):588–91.

    Article  PubMed  Google Scholar 

  58. van den Bergh RC, van Vugt HA, Korfage IJ, et al. Disease insight and treatment perception of men on active surveillance for early prostate cancer. BJU Int. 2010;105(3):322–8.

    Article  PubMed  Google Scholar 

  59. Latini DM, Hart SL, Knight SJ, et al. The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance. J Urol. 2007;178(3 Pt 1):826–31 (discussion 831–822).

    Article  PubMed  Google Scholar 

  60. Burnet KL, Parker C, Dearnaley D, Brewin CR, Watson M. Does active surveillance for men with localized prostate cancer carry psychological morbidity? BJU Int. 2007;100(3):540–3.

    Article  PubMed  Google Scholar 

  61. Pickles T, Ruether JD, Weir L, Carlson L, Jakulj F. Psychosocial barriers to active surveillance for the management of early prostate cancer and a strategy for increased acceptance. BJU Int. 2007;100(3): 544–51.

    Article  PubMed  Google Scholar 

  62. Johansson E, Bill-Axelson A, Holmberg L, Onelov E, Johansson JE, Steineck G. Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial. Eur Urol. 2009;55(2):422–30.

    Article  PubMed  Google Scholar 

  63. van den Bergh RC, Essink-Bot ML, Roobol MJ, Schroder FH, Bangma CH, Steyerberg EW. Do anxiety and distress increase during active surveillance for low risk prostate cancer? J Urol. 2010;183(5): 1786–91.

    Article  PubMed  Google Scholar 

  64. Cooperberg MR, Moul JW, Carroll PR. The changing face of prostate cancer. J Clin Oncol. 2005;23(32): 8146–51.

    Article  PubMed  Google Scholar 

  65. Miller DC, Gruber SB, Hollenbeck BK, Montie JE, Wei JT. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst. 2006;98(16):1134–41.

    Article  PubMed  Google Scholar 

  66. de la Rosette J, Ahmed H, Barentsz J, et al. Focal therapy in prostate cancer-report from a consensus panel. J Endourol. 2010;24(5):775–80.

    Article  PubMed  Google Scholar 

  67. Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol. 2004;172(4 Pt 1):1297–301.

    Article  PubMed  Google Scholar 

  68. Sherwin JC, Mirmilstein G, Pedersen J, Lawrentschuk N, Bolton D, Mills J. Tumor volume in radical prostatectomy specimens assessed by digital image analysis software correlates with other prognostic factors. J Urol. 2010;183(5):1808–14.

    Article  PubMed  Google Scholar 

  69. Uhlman MA, Sun L, Stackhouse DA, et al. Tumor percent involvement predicts prostate specific antigen recurrence after radical prostatectomy only in men with smaller prostate. J Urol. 2010;183(3):997–1001.

    Article  PubMed  CAS  Google Scholar 

  70. Nguyen CT, Jones JS. Focal therapy in the management of localized prostate cancer. BJU Int. 2010; 107(9):1362–8.

    Article  Google Scholar 

  71. Villers A, Lemaitre L, Haffner J, Puech P. Current status of MRI for the diagnosis, staging and prognosis of prostate cancer: implications for focal therapy and active surveillance. Curr Opin Urol. 2009;19(3): 274–82.

    Article  PubMed  Google Scholar 

  72. Jayram G, Eggener SE. Patient selection for focal therapy of localized prostate cancer. Curr Opin Urol. 2009;19(3):268–73.

    Article  PubMed  Google Scholar 

  73. Lindner U, Trachtenberg J. Focal therapy for localized prostate cancer -choosing the middle ground. Can Urol Assoc J. 2009;3(4):333–5.

    PubMed  Google Scholar 

  74. Onik G, Miessau M, Bostwick DG. Three-dimensional prostate mapping biopsy has a potentially significant impact on prostate cancer management. J Clin Oncol. 2009;27(26):4321–6.

    Article  PubMed  Google Scholar 

  75. Onik G, Barzell W. Transperineal 3D mapping biopsy of the prostate: an essential tool in selecting patients for focal prostate cancer therapy. Urol Oncol. 2008;26(5):506–10.

    Article  PubMed  Google Scholar 

  76. Crawford ED, Wilson SS, Torkko KC, et al. Clinical staging of prostate cancer: a computer-simulated study of transperineal prostate biopsy. BJU Int. 2005;96(7):999–1004.

    Article  PubMed  Google Scholar 

  77. Salomon G, Kollerman J, Thederan I, et al. Evaluation of prostate cancer detection with ultrasound real-time elastography: a comparison with step section pathological analysis after radical prostatectomy. Eur Urol. 2008;54(6):1354–62.

    Article  PubMed  Google Scholar 

  78. Braeckman J, Autier P, Garbar C, et al. Computer-aided ultrasonography (HistoScanning): a novel technology for locating and characterizing prostate cancer. BJU Int. 2008;101(3):293–8.

    Article  PubMed  Google Scholar 

  79. Braeckman J, Autier P, Soviany C, et al. The accuracy of transrectal ultrasonography supplemented with computer-aided ultrasonography for detecting small prostate cancers. BJU Int. 2008;102(11):1560–5.

    Article  PubMed  Google Scholar 

  80. Seitz M, Gratzke C, Schlenker B, et al. Contrast-enhanced transrectal ultrasound (CE-TRUS) with cadence-contrast pulse sequence (CPS) technology for the identification of prostate cancer. Urol Oncol. 2009;29(3):295–301.

    PubMed  Google Scholar 

  81. Lindner U, Weersink RA, Haider MA, et al. Image guided photothermal focal therapy for localized prostate cancer: phase I trial. J Urol. 2009;182(4):1371–7.

    Article  PubMed  CAS  Google Scholar 

  82. Kirkham AP, Emberton M, Hoh IM, Illing RO, Freeman AA, Allen C. MR imaging of prostate after treatment with high-intensity focused ultrasound. Radiology. 2008;246(3):833–44.

    Article  PubMed  Google Scholar 

  83. Rouviere O, Girouin N, Glas L, et al. Prostate cancer transrectal HIFU ablation: detection of local recurrences using T2-weighted and dynamic contrast-enhanced MRI. Eur Radiol. 2010;20(1):48–55.

    Article  PubMed  Google Scholar 

  84. Lambert EH, Bolte K, Masson P, Katz AE. Focal cryosurgery: encouraging health outcomes for unifocal prostate cancer. Urology. 2007;69(6):1117–20.

    Article  PubMed  Google Scholar 

  85. Onik G, Vaughan D, Lotenfoe R, Dineen M, Brady J. The “male lumpectomy”: focal therapy for prostate cancer using cryoablation results in 48 patients with at least 2-year follow-up. Urol Oncol. 2008;26(5):500–5.

    Article  PubMed  Google Scholar 

  86. Bahn DK, Silverman P, Lee Sr F, Badalament R, Bahn ED, Rewcastle JC. Focal prostate cryoablation: initial results show cancer control and potency preservation. J Endourol. 2006;20(9):688–92.

    Article  PubMed  Google Scholar 

  87. Muto S, Yoshii T, Saito K, Kamiyama Y, Ide H, Horie S. Focal therapy with high-intensity-focused ultrasound in the treatment of localized prostate cancer. Jpn J Clin Oncol. 2008;38(3):192–9.

    Article  PubMed  Google Scholar 

  88. Ahmed HU, Freeman A, Kirkham A, et al. Focal therapy for localized prostate cancer: a phase I/II trial. J Urol. 2011;185(4):1246–54.

    Article  PubMed  CAS  Google Scholar 

  89. ElFegoun AB, Barret E, Prapotnich D, et al. Focal therapy with high-intensity focused ultrasound for prostate cancer in the elderly. A feasibility study with 10 years follow-up. Int Braz J Urol. 2011;37(2):213–9 (discussion 220–212).

    Google Scholar 

  90. Mouraviev V, Madden JF. Focal therapy for prostate cancer: pathologic basis. Curr Opin Urol. 2009;19(2): 161–7.

    Article  PubMed  Google Scholar 

  91. Mouraviev V, Mayes JM, Polascik TJ. Pathologic basis of focal therapy for early-stage prostate cancer. Nat Rev Urol. 2009;6(4):205–15.

    Article  PubMed  Google Scholar 

  92. Eggener SE, Scardino PT, Carroll PR, et al. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol. 2007; 178(6):2260–7.

    Article  PubMed  Google Scholar 

  93. Ahmed HU, Emberton M. Re: Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol. 2008;180(2):780–1 (author reply 781–783).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, University Hospitals Leuven, Herestraat 49, Leuven, 3000, Belgium

    Hendrik Van Poppel M.D., Ph.D. & Steven Joniau M.D.

Authors
  1. Hendrik Van Poppel M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Steven Joniau M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hendrik Van Poppel M.D., Ph.D. .

Editor information

Editors and Affiliations

  1. , Department of Surgery, Duke Cancer Institute, Room 1089 Duke South, Durham, 27710, North Carolina, USA

    Thomas J. Polascik

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Van Poppel, H., Joniau, S. (2013). Active Surveillance and Focal Therapy: A European Perspective. In: Polascik, T. (eds) Imaging and Focal Therapy of Early Prostate Cancer. Current Clinical Urology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-182-0_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-62703-182-0_3

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-62703-181-3

  • Online ISBN: 978-1-62703-182-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation